Philips, SEC reach $62M settlement in China probe

Today's Big News

May 15, 2023

UPDATED: FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy


Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?


UPDATED: Sarepta rewarded by Wall Street for FDA committee shocker, with accelerated nod now more likely


Philips reaches $62M SEC settlement over alleged violations of anti-bribery law in China


After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M+

 

Featured

UPDATED: FDA advisers narrowly vote in favor of Sarepta's DMD gene therapy

FDA advisers have narrowly voted in favor of Sarepta’s gene therapy for patients with Duchenne muscular dystrophy, a stunning decision that runs counter to regulators who expressed skepticism heading into the meeting. 
 

Top Stories

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

Pfizer's $43 billion Seagen deal is now up for its high-stakes review at the FTC. The review comes after the agency said it would take a tougher stance toward biopharma megamergers.

UPDATED: Sarepta rewarded by Wall Street for FDA committee shocker, with accelerated nod now more likely

Sarepta was handsomely rewarded by investors early Monday after FDA advisers surprisingly voted in favor of the accelerated approval path for the company’s Duchenne muscular dystrophy gene therapy on Friday evening. 

Philips reaches $62M SEC settlement over alleged violations of anti-bribery law in China

For the second time in a decade, Philips has agreed to settle with the U.S. Securities and Exchange Commission over alleged misconduct in its international operations.

After Hemgenix approvals, uniQure cashes out some of its royalty rights for $375M-plus

Months after the U.S. and European approvals of its CSL-partnered hemophilia A gene therapy, uniQure is selling some royalty rights for up to $400 million.

Identifying 'gems' before others do: J&J exec gives insider's look at dealmaking spree

Whether it’s returning to CAR-Ts, swooping in to pick up a Parkinson’s asset from a sinking biotech or setting up a spinout company to pursue its neuroscience ambitions, Janssen has been busy in recent months.

Embecta dives deeper into Type 2 diabetes tech with Tidepool team-up

Embecta has teamed up with Tidepool to add an automated insulin delivery algorithm to its insulin patch pump to create a closed-loop diabetes management system for Type 2 users.

UPDATED: After Supreme Court rejection, Teva mulls options in GSK 'skinny label' feud

The Supreme Court’s brief involvement in the "skinny label" feud between GSK and Teva Pharmaceuticals has ended in a rejection—even after the United States’ top lawyer urged the Justices to take up the case.

Omeq Medical bags FDA approval for epidural guidance device

A medical device that aims to make the administration of epidurals more reliable and safer has been cleared by the FDA, giving its developer Omeq Medical its first approved product.

New Eli Lilly-backed neurological disease biotech Nido unveils with $109M

Nido Biosciences is exiting stealth mode with $109 million in hand to develop new precision medicines for neurological diseases, with a lead asset that takes aim at Kennedy’s disease, a rare degenerative disorder.

Astellas' menopause drug crosses FDA finish line after costly delay

The decision came nearly three months after the drug's original FDA decision date.

Envivo’s smart capsule opens a window on gut health

Want to know what’s going on across the length of your gastrointestinal tract? Swallowing a smart capsule device developed by Envivo Bio could give you the answer, according to a new study.
 
Fierce podcasts

Don't miss an episode

'The Top Line': The final installment of a series on Narcan, plus this week's headlines

This week on "The Top Line," we're concluding our miniseries on Narcan the nasal spray. It is the first naloxone product to be approved for use without a prescription.
 

Resources

Whitepaper

ChatGPT in Drug Discovery: Rise of Large Language Models

ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations.
Whitepaper

Discovering High-Affinity, Functional Anti-GLP-1R Antibodies

Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties.
eBook

Decentralized Clinical Trials: The Complete Guide for 2023

Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success.
Research

How Lilly’s Legal and Library Services Empower Teams Across the Drug Development Pipeline

What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how.
Whitepaper

Medical Affairs Metamorphosis VI: The Changing Face of Stakeholder Engagement

This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing.
Research

Maximizing Clinical Trial Success

Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies
Whitepaper

eConsent: Flexible Consent Through Enabling Technologies

How can eConsent provide a more flexible approach to informed consent?
Whitepaper

Running Decentralized Trials at Scale

Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment.
Whitepaper

Designing an Optimal APAC Clinical Supply Chain

Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific.
Whitepaper

Key Clinical Supply Issues Sponsors Should Consider with their CRO

As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs.

Whitepaper

Specialized Expertise for Management of Clinical Supply Budgets

For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management.
Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Roles and Responsibilities of Specialized Clinical Supply Experts

How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis.
Whitepaper

Questions You Need to Ask Your CRO About Clinical Supply

Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

12-14
Jun
San Diego, CA
13
Jun
Free Virtual Event
20-22
Jun
Free Virtual Event
22
Jun
Free Virtual Event
18-19
Jul
July 18-19, 2023 | Jersey City, NJ

View all events